Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory studies prevented the virus from developing drug resistance—a persistent problem with current therapies for infants. RSV is a seasonal infection that circulates globally and can be especially dangerous for people at opposite ends of the age spectrum: infants and older adults. Vaccines are available for those who are 65 and older (GlaxoSmithKline’s Arexvy, Pfizer’s ABRYSVO and Moderna’s mRESVIA), but there is still no available vaccine for infants who are among the most vulnerable.
This article was originally published on MedicalXpress.com
